A5019598632- Diabetes Treatment and Management
- Pharmacology and Obesity Treatment
- Lipoproteins and Cardiovascular Health
- RNA modifications and cancer
- Metabolism, Diabetes, and Cancer
- Lung Cancer Treatments and Mutations
- Diabetes Management and Research
- Genomics and Rare Diseases
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Advancements in Battery Materials
- Aquaculture disease management and microbiota
- Pancreatic and Hepatic Oncology Research
- Market Dynamics and Volatility
- Cancer Genomics and Diagnostics
- Psoriasis: Treatment and Pathogenesis
- Cancer-related Molecular Pathways
- Advanced Battery Materials and Technologies
- Cancer-related gene regulation
- Ferroptosis and cancer prognosis
- Health and Medical Research Impacts
- Genetic and Kidney Cyst Diseases
- Thermal Expansion and Ionic Conductivity
- Financial Literacy, Pension, Retirement Analysis
- Biosimilars and Bioanalytical Methods
Wuhan University of Technology
2023-2025
Xizang Minzu University
2025
University of International Business and Economics
2020-2025
Shanghai University
2024
First Affiliated Hospital of Jinan University
2024
Shanghai Institute of Nutrition and Health
2019-2023
Beijing International Studies University
2023
Beijing Anzhen Hospital
2022
Chinese Academy of Fishery Sciences
2021
Luoyang Institute of Science and Technology
2021
BackgroundMazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss up to 6.4% at doses 6 mg in Chinese adults with overweight obesity. We further explored the safety efficacy of mazdutide dosed 9 10 mg.MethodsIn this randomised, placebo-controlled, multiple-ascending-dose phase 1b trial, we enrolled (aged 18-75 years, both inclusive) (body-mass index [BMI] ≥24 kg/m2) accompanied by...
Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy safety of 24-week treatment mazdutide up to 6 mg in Chinese overweight adults or with obesity, as an interim analysis randomised, two-part (low doses high dose 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight (body-mass index [BMI] ≥24 kg/m
OBJECTIVE We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, once-weekly glucagon-like peptide 1 glucagon receptor dual agonist, in Chinese patients with type diabetes. RESEARCH DESIGN AND METHODS Adults diabetes inadequately controlled diet exercise alone or stable metformin (glycated hemoglobin A1c [HbA1c] 7.0–10.5% [53–91 mmol/mol]) were randomly assigned receive 3 mg mazdutide (n = 51), 4.5 49), 6 1.5 open-label...
Background The phosphatidylinositol 3-kinase (PI3K) is frequently hyperactivated in cancer and plays important roles both malignant immune cells. effect of PI3Kα inhibitors on the tumor microenvironment (TME) remains largely unknown. Here, we investigated modulation TME by a clinical PI3Kα-specific inhibitor CYH33. Methods activity CYH33 against panel murine tumors immune-competent context or athymic mice was detected. Single-cell RNA sequencing multi-parameter flow cytometry were performed...
IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity type 2 diabetes. The aim this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate safety, tolerability, pharmacokinetics efficacy in Chinese adults with overweight or obesity.This enrolled (body mass index [BMI]≥24 kg/m2) accompanied by hyperphagia and/or at least one comorbidity (BMI≥28 from six centres China....
Abstract The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) evaluate the safety efficacy IBI362 (LY3305677), GLP-1 glucagon dual agonist, in Chinese patients with T2D. A total 43 T2D were enrolled three cohorts nine centres China randomised each...
Abstract Background Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C). We conducted the first randomized, placebo-controlled clinical trial Chinese with HeFH to assess efficacy safety tafolecimab, a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. Methods Patients diagnosed by Simon Broome criteria...
The impact of weather-induced mood on corporate behaviour has become an important debate in both literature and practice. Our study investigates the effects sunshine-induced CEOs' R&D investment decisions, using a sample Chinese A-share listed firms from 2010 to 2019. findings suggest that sunshine exposure may enhance investment. influence weather is significantly more pronounced led by CEOs with high educational attainment, academic backgrounds, roles as board chairs, compensation....
Sepsis shock is caused by a systemic infection characterized circulatory disorders and metabolic abnormalities. Microorganisms or their toxins enter the bloodstream, releasing inflammatory mediators triggering reactions, leading to multiple organ dysfunction even failure. To explore new treatment methods, we studied improvement effect of sesamoside on response in septic shock. We performed vitro experiments animal models. found that reduced cytokines such as TNF-α, IL-6, IL-1β, iNOS, NO....
Kidney aging leads to an increased incidence of end-stage renal disease (ESRD) in the elderly, and is a complex biological process controlled by signaling pathways transcription factors. Podocyte senescence plays central role injury resulting from kidney aging. Here, we demonstrated critical C/EBPα podocyte generating genetically modified mouse model chronological which was selectively deleted podocytes overexpressing cultured podocytes, premature induced treatment with adriamycin. Moreover,...
Abstract Aberrant differentiation, driven by activation of normally silent tissue-specific genes, results in a switch cell identity and often leads to cancer progression. The underlying genetic epigenetic events are largely unexplored. Here, we report ectopic the hepatobiliary-, intestinal- neural-specific gene one cut homeobox 2 ( ONECUT2) various subtypes lung cancer. ONECUT2 expression was associated with poor prognosis RAS-driven adenocarcinoma. overexpression promoted malignant growth...
Abstract Functional hierarchy is prevalent in biological systems owing to natural evolution. Efforts replicate these structures artificial materials have gained traction science. Although hierarchical are fabricated at different scales based on site‐specific interactions using ABC‐type block copolymers (BCPs), the fabrication of such AB‐type BCPs via a simple and efficient method remains challenging. Herein, class amphiphilic (PDen m ‐ b ‐PAChol n ) reported comprising dendronized...
Abstract Phosphoinositide-3 kinase alpha-specific inhibitors (PI3Kαi) displayed promising potential for the treatment of esophageal squamous cell carcinoma (ESCC) with frequent activation in PI3K signaling. However, acquired resistance is likely to develop and limit efficacy PI3Kαi like other targeted therapies. To identify genomic adaptation PI3Kαi, we applied whole-genome sequencing detected gene mutation amplification four lines ESCC cells established adapted a novel CYH33. Particularly,...
Because of the considerable tumor heterogeneity in gastric cancer (GC), only a limited group patients experiences positive outcomes from immunotherapy. Herein, we aim to develop predictive models related glycosylation genes provide more comprehensive understanding immunotherapy for GC. RNA sequencing (RNA-seq) data and corresponding clinical were obtained GEO TCGA databases, glycosylation-related GlycoGene DataBase. We identified 48 differentially expressed established prognostic model...
Abstract Phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitors are currently evaluated for the therapy of esophageal squamous cell carcinoma (ESCC). It is great importance to identify potential biomarkers predict or monitor efficacy PI3Kα in an aim improve clinical responsive rate ESCC. Here, ESCC PDXs with CCND1 amplification were found be more sensitive CYH33, a novel PI3Kα-selective inhibitor trials treatment advanced solid tumors including Elevated level cyclin D1, p21 and Rb was...
Tafolecimab, a novel fully human monoclonal antibody targeting PCSK9, has been assessed in Chinese healthy volunteers and patients with hypercholesterolemia. This analysis is to develop qualify population pharmacokinetics (PopPKs)/LDL-C model characterize tafolecimab PK LDL-C profiles, evaluate the impact of potential covariates on tafolecimab, estimate individual predicted exposure, decreasing, furthermore, explore exposure-response relationship support clinical use. Data from six trials...
Through linkage and candidate gene screening, many breast cancer (BC) predisposition genes have been identified in the past 20 years. However, majority of genetic risks that contribute to familial BC remains undetermined. In this study, we revisited whole exome sequencing datasets from non-BRCA1/2 patients, search for novel genes. Based on infinite mutation model, supposed rare non-silent variants cooccurred between TCGA-germline datasets, might play a contributing role. our analysis, not...
Introduction: Currently approved proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies demonstrated robust low density lipoprotein cholesterol (LDL-C)-lowering efficacy at doses up to 420 mg monthly, while longer dosing intervals are largely unexplored. We assessed the and safety of tafolecimab, a potential long-acting fully human PCSK9 antibody, in Chinese patients with non-familial hypercholesterolemia (ClinicalTrials.gov, NCT04289285). Methods: Patients were...
Interleukin (IL) 23p19 monoclonal antibodies were efficacious and safe in the treatment of psoriasis. A first-in-human (FIH) study was conducted to evaluate safety, tolerability, pharmacokinetics (PK) immunogenicity IBI112, a novel IL-23p19 antibody.In this FIH, randomized, double-blind, placebo-controlled, single-ascending-dose study, subcutaneous (SC, 5-600 mg) or intravenous (IV, 100 600 placebo administered eligible healthy subjects. Safety assessed by physical examinations, vital signs,...